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We previously reported the ﬁrst ‘reverse antibiotic’ (RA), nybomycin (NYB), which showed a unique
antimicrobial activity against Staphylococcus aureus strains. NYB speciﬁcally suppressed the growth
of quinolone-resistant S. aureus strains but was not effective against quinolone-susceptible strains.
Although NYB was ﬁrst reported in 1955, little was known about its unique antimicrobial activity
because it was before the synthesis of the ﬁrst quinolone (‘old quinolone’), nalidixic acid, in 1962.
Following our re-discovery of NYB, we looked for other RAs among natural substances that act on
quinolone-resistant bacteria. Commercially available ﬂavones were screened against S. aureus, including
quinolone-resistant strains, and their minimum inhibitory concentrations (MICs) were compared using
the microbroth dilution method. Some of the ﬂavones screened showed stronger antimicrobial activity
against quinolone-resistant strains than against quinolone-susceptible ones. Amongst them, apigenin
(API) was the most potent in its RA activity. DNA cleavage assay showed that API inhibited DNA gyrase
harbouring the quinolone resistancemutation gyrA(Ser84Leu) but did not inhibit ‘wild-type’ DNA gyrase
that is sensitive to levoﬂoxacin. An API-susceptible S. aureus strain Mu50 was also selected using agar
plates containing 20mg/L API.Whole-genome sequencing of selectedmutant strains was performed and
frequent back-mutations (reverse mutations) were found among API-resistant strains derived from the
API-susceptible S. aureus strains. Here we report that API represents another molecular class of natural
antibiotic having RA activity against quinolone-resistant bacteria.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND. Introduction
The emergence of bacteria resistant to antibiotics has become a
orldwideconcern.Althoughﬁndingeffective treatments for resis-
ant strains is a top priority, few tools are available due to difﬁculty
n thedevelopmentofnewantibiotics by thepharmaceutical indus-
ry. The history of antibacterial agents tells us that introduction of
new antibiotic is always followed by the appearance of resistant
icro-organisms, with no exceptions [1]. Therefore, development
f new drugs based on a completely novel concept is awaited.
We have previously reported nybomycin (NYB) as a can-
idate for such novel therapeutics [2]. NYB, produced by an
ctinobacterium, was ﬁrst reported in 1955 [3]. At that time,
uinolone-resistant bacteria had not been detected since clinical
ntroduction of the quinolones did not start until the early 1960s
4]. Therefore, features of NYB with regard to quinolone resis-
ance have not been studied. Our re-discovery of NYB as a ‘reverse
ntibiotic’ (RA) was brought about by screening of Actinobacteria
∗ Corresponding author. Tel.: +81 3 5802 1040; fax: +81 3 5684 7830.
E-mail address: khiram06@juntendo.ac.jp (K. Hiramatsu).
ttp://dx.doi.org/10.1016/j.ijantimicag.2015.09.006
924-8579/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cultures using quinolone-resistant meticillin-resistant Staphylo-
coccus aureus (MRSA) as well as quinolone-susceptible S. aureus
clinical strains. We looked for Actinobacteria supernatants that
suppressed the growth of MRSA. The screening hit an actinobac-
terial strain, Streptomyces hyalinum MB891-A1, which produced a
substance that had strong growth inhibition against MRSA strain
Mu50. However, surprisingly the substance exhibited no activity
against a meticillin-susceptible S. aureus (MSSA) type strain FDA
209P. The ﬁnding of this substance, identiﬁed as NYB, prompted
us to determine the mode of antimicrobial activity of NYB. We
noticed that MRSA strain Mu50 was resistant to quinolones but
was susceptible to NYB, whereas the MSSA strain FDA 209P
was quinolone-susceptible but NYB-resistant. NYB was found to
speciﬁcally suppress the growth of quinolone-resistant S. aureus
carrying mutation(s) in the quinolone resistance-determining
region (QRDR) of gyrA, encoding the A subunit of DNA gyrase. How-
ever, NYBwasnot active against strains carrying intact orwild-type
gyrA with no QRDRmutations. In addition, S. aureus mutant strains
that acquired NYB resistance became quinolone-susceptible, and
they were found to have reverse mutations to regain the ‘wild-
type’ sequence in theQRDR. Biochemical analysis also revealed that
NYB targets and inhibits the function of the mutated GyrA subunit.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hus, we found that the antimicrobial activity of NYB is comple-
entary to that of quinolones.We therefore designated such a class
f antibiotics represented by NYB as ‘reverse antibiotics’ (RAs).
During our attempt to screen for newRA candidates, we noticed
n old report demonstrating a weak inhibitory effect of quercetin
nd related ﬂavones on Escherichia coli DNA gyrase [5]. Flavones
roduced by plants are commonly used in folk remedies, thus
heir antibacterial activity has been studied previously [6]. How-
ver, the results were not impressive against the tested bacterial
trains, including S. aureus [7,8]. Using quinolone-susceptible and
resistant S. aureus strains, we found that some ﬂavones do have
ctivity against S. aureus, and a few of them inhibited the growth
f quinolone-resistant strains much better than that of susceptible
nes.
Among such ﬂavones, apigenin (API) was found to be the most
onspicuous in its activity. In this report, we describe the mode of
ction of API and its property as another class of RA.
. Materials and methods
.1. Bacterial strains
A total of 36 S. aureus strains used in this study were isolated
romJapan, theUKand theUSA (Table1). All of the strainshavebeen
escribed previously. Clinical S. aureus strains MS5935, MR5867,
S5952 and MR6009 and their stepwise quinolone-resistant
utants have been described previously [9]. Staphylococcus aureus
CTC 8325 and FDA 209P are MSSA type strains [2], and S. aureus
315 is a quinolone-susceptible MRSA [10]. KSA36, KBSA72 and
BSA56 are clinical MRSA isolated from Japanese hospitals in 2005
2]. The remaining strains are clinical isolates with either reduced
usceptibility [vancomycin-intermediate S. aureus (VISA)] (n=7) or
esistance [vancomycin-resistant S. aureus (VRSA)] (n=4) to van-
omycin.
.2. Antibiotic susceptibility testing
Minimum inhibitory concentrations (MICs) were determined
y the microbroth dilution method with an inoculum size of
04 CFU/well in a ﬁnal volume of 100L. The procedure was per-
ormed according to Clinical and Laboratory Standards Institute
CLSI) guidelines [11].
API was obtained from Tokyo Chemical Industry Co., Ltd.
Tokyo, Japan). Dimethyl sulfoxide (DMSO) was used to prepare
1024mg/L API solution. Water containing up to 0.1M NaOH was
sed for the preparation of quinolones. All solutions were diluted
ith cation-adjusted Mueller–Hinton broth (CA-MHB) [BD BBLTM
ueller–Hinton II Broth (Cation-Adjusted); BDDiagnostic Systems,
parks, MD] for MIC measurement.
.3. Mutant selection
Staphylococcus aureus strainMu50was inoculated in eight tubes
ontaining 4mL of tryptic soy broth (TSB) (BD Diagnostic Sys-
ems). After overnight incubation at 37 ◦C, the eight full-growth
ubes were concentrated by 10-fold and were plated individually
n a 150mm×15mm Petri dish (BD FalconTM 35-1058; BD Bio-
ciences, Franklin Lakes, NJ) containing 75mL of Mueller–Hinton
garmedium(BDDiagnostic Systems)with20mg/LAPI.Onecolony
rom each plate was picked and subjected to further investigation.
.4. PCR ampliﬁcation and sequencing of the quinolone
esistance-determining regions of gyrA and parC
Five sets of forward and reverse primers, respectively, were
sed: 5′-TTAGGTGATCGCTTTGGAAGATATAG-3′ and 5′-TACCATTtimicrobial Agents 46 (2015) 666–673 667
GGTTCGAGTGTCG-3′ forparC; 5′-GGATTAAATGAACAAGGTATGACA
CCG-3′ and 5′-TAGTCATACGCGCTTCAGTATAACG-3′ for gyrA;
5′-CAGCGTTAGATGTAGCAAGT-3′ and 5′-CAGGACCTTCAATATCCT
CC-3′ for gyrB; 5′-CGTAAGGACGTCTTGCCTGA-3′ and 5′-GGCTCA
TGACCAGCTGAACT-3′ for rsbU; and 5′-CCAGCAATTGGTAAAAT
CCAA-3′ and 5′-TGGTTCAAAACCAAGGGATG-3′ for murC.
Nucleotide sequences were converted to amino acid sequences
and were aligned with the amino acid sequences of the type
II topoisomerases (ParC, GyrA and GyrB) of the parent strain
Mu50 and reference strain FDA 209P to identify non-synonymous
(or missense) mutations. Sequencing of the ampliﬁed DNA was
done using a BigDye® Terminator v.3.1 Cycle Sequencing Kit
(Applied Biosystems, Life Technologies, Carlsbad, CA) and an
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Life
Technologies).
2.5. Whole-genome sequencing and mutation detection
The whole genome sequences of in vitro-selected API-resistant
mutants were determined using a MiSeq Genome Analyzer (Illu-
mina, Inc., San Diego, CA). DNA extraction was performed using
a QIAGEN Genome-tip System (QIAGEN, Hilden, Germany), and
library preparations were performed using Nextera XT DNA sam-
ple preparation kits (Illumina, Inc.). Pools of eight samples were
sequenced on the Illumina MiSeq platform, and 250-bp end reads
were generated. Reads from bacterial strains were then mapped
to the reference whole genome sequence of strain Mu50 (Gen-
Bank accession no. NC 002758.2) and mutations were identiﬁed
using Tablet v.1.13.04.22 (The James Hutton Institute, Aberdeen,
UK). The identiﬁed single nucleotide polymorphism were then
veriﬁed by re-sequencing using an Applied Biosystems 3730 Cap-
illary Sequencer (Applied Biosystems Ltd., Tokyo, Japan) for each
locus.
2.6. Cytokilling assay
Overnight cultures of tested strains in TSB were diluted and ca.
0.5mL of 106 CFU/mL was transferred into 4.5mL of fresh CA-MHB
containing 0, 8, 16, 20, 24 or 32mg/L API. Test tubes were incu-
bated with gentle shaking and 0.1mL portions of the culture were
harvested to a drug-free plate at 0, 0.5, 1, 3, 5, 7 and 24h. The
grown colonies were counted and plotted on a graph. The cultiva-
tion temperature of the test strainswas37 ◦C forMu50andKBSA56.
These strains were also tested at a cultivation temperature at
43 ◦C.
2.7. Demonstration of gyrase inhibition by DNA cleavage assay
The assay was based on an established system as described by
Fisher and Pan [12]. Brieﬂy, supercoiled plasmid DNA pTWV228
(a pBR322 derivative) (TaKaRa Bio Inc., Kusatsu, Japan) was pre-
incubated in the presence of either API or levoﬂoxacin, followed
by addition of GyrB in combination with either the wild-type or
mutated GyrA proteins and then incubated at 25 ◦C for 1h. The
following analyses, including determination of IC50 values (50%
inhibitory concentration), were carried out as described previously
[2].
3. Results
By testing 104 ﬂavones, we found at least three ﬂavones that
shared preferential antimicrobial activity against MRSA Mu50
compared with MSSA FDA 209P, including API, myricetin-3,7,3′,4′-
tetramethyl ether and isopratol. Their MICs are shown in Table 2.
Among the three ﬂavones, API showed themost typical MIC proﬁle
of a RA. We therefore decided to study API.
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Table 1
Staphylococcus aureus strains used in this study.
Straina Year of isolation Country (state) of isolation Category Reference
FDA 209P (NCTC 7447, ATCC 6538) 1948b UK MSSA [2]
Mu50 (ATCC 700699, NRS1) 1996 Japan MRSA (VISA) [10]
MS5935 1996b Japan MSSA [9]
MS5935 1st step 1996b Japan MSSA [9]
MS5935 2nd step 1996b Japan MSSA [9]
MS5935 3rd step 1996b Japan MSSA [9]
MS5935 4th step 1996b Japan MSSA [9]
MR5867 1996b Japan MRSA [9]
MR5867 1st step 1996b Japan MRSA [9]
MR5867 2nd step 1996b Japan MRSA [9]
MR5867 3rd step 1996b Japan MRSA [9]
MR5867 4th step 1996b Japan MRSA [9]
MS5952 1996b Japan MSSA [9]
MS5952 1st step 1996b Japan MSSA [9]
MS5952 2nd step 1996b Japan MSSA [9]
MS5952 3rd step 1996b Japan MSSA [9]
MR6009 1996b Japan MRSA [9]
MR6009 1st step 1996b Japan MRSA [9]
MR6009 2nd step 1996b Japan MRSA [9]
MR6009 3srd step 1996b Japan MRSA [9]
MR6009 4th step 1996b Japan MRSA [9]
NCTC 8325 1943 UK MSSA [2]
N315 1982 Japan MRSA [10]
VRS1 2002 USA VRSA [2]
HIP09143 2000 USA MRSA (VISA) [2]
HIP09662 2000 USA MRSA (VISA) [2]
NRS118 2002 USA MRSA (VISA) [2]
VRS4 2005 USA VRSA [2]
HIP07920 1998 USA MRSA (VISA) [2]
HIP5836 (NJ) 1997 USA MRSA (VISA) [2]
KSA36 2005 Japan MRSA [2]
VRS3a 2004 USA VRSA [2]
KBSA72 2005 Japan MRSA [2]
VRS5 2005 USA VRSA [2]
KBSA56 2005 Japan MRSA [2]
HIP07930 1999 USA MRSA (VISA) [2]
MSSA, meticillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; VISA, vanco
a Alternative names for each strain are given in parenthesis if they have been used quit
b Year of accession (not year of isolation).
Table 2
Minimum inhibitory concentrations (MICs) of three ﬂavones against quinolone-
resistant Staphylococcus aureus strainMu50andquinolone-susceptible S. aureus FDA
209P.
Compound MIC (mg/L)
Mu50 FDA 209P
Apigenin 4 >128
Myricetin-3,7,3′ ,4′-tetramethyl ether 8 128
Isopratol 16 >128
3
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represents API to have no effect on bacterial growth (NCTC 8325,Norﬂoxacin 128 0.25
Levoﬂoxacin 8 ≤0.06
.1. Anti-quinolone-resistance activity of apigenin
The antibacterial activity of API was determined for quinolone-
usceptible and -resistant S. aureus strains and was compared
ith that of several ﬂuoroquinolones (norﬂoxacin, oﬂoxacin, levo-
oxacin, ciproﬂoxacin, sparﬂoxacin and tosuﬂoxacin) and NYB
Table 3). Although the growth inhibitory activity was 16-fold
eaker than NYB, API showed the feature of a RA, i.e. stronger
ntimicrobial activity against quinolone-resistant S. aureus Mu50
han against quinolone-susceptible FDA 209P. To determine the
elationship between API susceptibility and quinolone resistance,
sogenic sets of quinolone-resistantmutant strainswere tested. The
our parent strains (MS5935, MS5952, MR5867 and MR6009) are
linical isolates, and their stepwise quinolone-resistant mutants
re their in vitro derivatives [9]. Table 3 shows that all four parent
trains having wild-type ParC and GyrA proteins were susceptiblemycin-intermediate S. aureus; VRSA, vancomycin-resistant S. aureus.
e frequently in publications.
to the six quinolone antibiotics but were resistant to API and
NYB. The activity of quinolones decreased with the accumulation
of mutations in the QRDRs of ParC and GyrA. API gained activ-
ity with the procession of quinolone resistance. The MIC of API
dropped from 128mg/L to ≤8mg/L with gyrA(Ser84Leu) mutation.
The third-step mutant of MR6009 with parC(Ser80Tyr, Glu84Lys)
double mutations also showed increased susceptibility towards
API.
Subsequently, a total of 17 clinically isolated strains that were
ether MSSA, MRSA, VISA or VRSA with variable types of QRDR
mutations were tested (Table 4). Three strains having wild-type
QRDRs showed resistance to API. The other 14 strains having
gyrA(Ser84Leu) mutation showed an API MIC of ≤4mg/L. Three
strains that acquired gyrA(Ser84Leu, Glu88Gly) mutations showed
anMICof0.5mg/Landwere themost susceptible toAPI. The reverse
pattern ofMIC values between quinolones and NYBwas once again
observed with API (Fig. 1).
3.2. Cytokilling assay
Fig. 2a illustrates the time-dependent cytokilling activity of API
against 17 S. aureus strains that were used for the MIC measure-
ment described above. In the experiment, 20mg/L API was used.
The results roughly gave three patterns of killing curves: pattern 1N315); pattern 2 represents API to have some effect to inhibit bac-
terial growth but strains increased the number of cells after 7h
of incubation (FDA 209P, HIP09662, NRS118, HIP5836, NRS118,
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Table 3
Apigenin (API) is active against Staphylococcus aureus strains with a gyrA(Ser84Leu) mutation.
Straina MIC (mg/L)b QRDR AA substitutionsc
NOR OFX LVX CIP TSX SPX NYB API ParC GyrA
FDA 209P (NCTC
7447, ATCC
6538)
0.25 0.125 ≤0.06 0.125 ≤0.06 ≤0.06 64 128 – –
Mu50 (ATCC
700699, NRS1)
128 16 8 32 >128 16 0.25 4 Ser80Phe Ser84Leu
MS5935 1 0.25 0.125 0.25 0.125 ≤0.06 >64 128 – –
MS5935 1st step 16 1 0.5 2 1 ≤0.06 >64 128 Ser80Phe –
MS5935 2nd step 128 16 8 32 64 16 1 4 Ser80Phe Ser84Leu
MS5935 3rd step 128 128 64 128 >128 32 1 4 Ser80Phe, Glu84Lys Ser84Leu
MS5935 4th step 128 >128 >128 128 >128 128 32 4 Ser80Phe, Glu84Lys Ser84Leu, Glu88Val
MR5867 1 0.25 0.125 0.25 ≤0.06 ≤0.06 >64 >128 – –
MR5867 1st step 16 1 0.5 2 0.25 ≤0.06 >64 128 Glu84Lys –
MR5867 2nd step 64 16 8 32 8 8 0.25 8 Glu84Lys Ser84Leu
MR5867 3rd step >128 64 16 128 >128 16 0.25 4 Ser80Phe, Glu84Lys Ser84Leu
MR5867 4th step >128 >128 >128 128 >128 128 0.25 4 Glu84Lys, Ser80Phe Ser84Leu, Glu88Lys
MS5952 1 0.25 0.125 0.5 0.5 <0.06 >64 128 – –
MS5952 1st step 16 1 0.5 2 2 0.125 >64 128 Ser80Tyr –
MS5952 2nd step 16 8 4 8 8 8 0.5 8 Ser80Tyr Ser84Leu
MS5952 3rd step 128 64 16 64 >128 16 0.5 2 Ser80Tyr, Ala116Val Ser84Leu
MR6009 1 0.25 0.125 0.25 <0.06 <0.06 >64 128 – –
MR6009 1st step 16 1 0.5 2 1 <0.06 >64 128 Ser80Tyr –
MR6009 2nd step 64 16 4 32 16 4 >64 128 Ser80Tyr Glu88Lys
MR6009 3rd step >128 32 16 128 >128 8 4 4 Ser80Tyr, Glu84Lys Glu88Lys
MR6009 4th step >128 >128 >128 128 >128 128 0.25 4 Ser80Tyr, Glu84Lys Ser84Leu Glu88Lys
MIC,minimum inhibitory concentration; NOR, norﬂoxacin; OFX, oﬂoxacin; LVX, levoﬂoxacin; CIP, ciproﬂoxacin; TSX, tosuﬂoxacin; SPX, sparﬂoxacin; NYB, nybomycin; QRDR,
quinolone resistance-determining region; AA, amino acid.
a Four isogenic sets of strains were used.
b MICs≤4mg/L are in bold.
c ‘–’ indicates no AA substitution.
Table 4
Minimum inhibitory concentrations (MICs) of six quinolones, nybomycin (NYB) and apigenin (API) against 17 clinically isolated Staphylococcus aureus strains.
Strain Country Year of
isolation
AA
substitutiona
MIC (mg/L)b
ParC GyrA NOR OFX LVX CIP TSX SPX NYB API
NCTC 8325 UK 1943 MSSA w/t w/t 1 0.25 0.125 0.25 ≤0.06 0.125 >64 >128
FDA 209P UK 1948 MSSA w/t w/t 0.25 0.125 ≤0.06 0.125 ≤0.06 ≤0.06 64 128
N315 Japan 1982 MRSA w/t w/t 1 0.25 0.125 0.25 ≤0.06 ≤0.06 64 >128
Mu50 Japan 1996 MRSA Ser80Phe Ser84Leu 128 16 8 32 >128 16 0.25 4
VRS1 USA 2002 VRSA Ser80Phe Ser84Leu >128 32 16 128 4 8 0.125 4
HIP07920 USA 1998 MRSA Glu84Lys Ser84Leu 16 16 8 16 4 16 0.25 4
HIP5836 (NJ) USA 1997 MRSA Ser80Tyr Ser84Leu 128 64 8 16 32 32 0.5 2
HIP07930 USA 1999 MRSA Ile45Met,
Ser80Phe
Ser84Leu 16 16 8 16 16 16 0.25 4
NRS118 USA 2002 MRSA Ser80Phe,
Ser81Pro
Ser84Leu 128 64 32 32 >128 32 0.25 4
VRS3a USA 2004 VRSA Ser80Tyr,
Glu84Lys
Ser84Leu 128 32 16 64 >128 16 0.125 2
HIP09662 USA 2000 MRSA Ser80Phe,
Glu84Gly
Ser84Leu 64 32 32 32 >128 16 1 4
VRS5 USA 2005 VRSA Ser80Tyr,
Glu84Gly
Ser84Leu >128 64 32 >128 >128 16 ≤0.06 2
HIP09143 USA 2000 MRSA Ser80Phe,
Glu84Lys
Ser84Leu >128 64 32 64 >128 16 0.25 2
VRS4 USA 2005 VRSA Ser80Tyr,
Glu84Gly
Ser84Leu,
Glu88Lys
>128 >128 >128 >128 >128 >128 ≤0.06 2
KSA36 Japan 2005 MRSA Ser80Tyr Ser84Leu,
Glu88Gly
>128 >128 >128 128 >128 128 ≤0.06 0.5
KBSA72 Japan 2005 MRSA Ser80Tyr,
Glu84Lys
Ser84Leu,
Glu88Gly
>128 >128 >128 128 >128 128 ≤0.06 0.5
KBSA56 Japan 2005 MRSA Ser80Tyr,
Glu84Val
Ser84Leu,
Glu88Gly
128 >128 >128 64 >128 >128 ≤0.06 0.5
AA, amino acid; NOR, norﬂoxacin; OFX, oﬂoxacin; LVX, levoﬂoxacin; CIP, ciproﬂoxacin; TSX, tosuﬂoxacin; SPX, sparﬂoxacin; NYB, nybomycin; API, apigenin;MSSA,meticillin-
susceptible S. aureus; MRSA, methicillin-resistant S. aureus; VRSA, vancomycin-resistant S. aureus.
a ‘w/t’ stands for wild-type (identical to strain FDA 209P).
b MICs≤4mg/L are in bold.
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tant toquinolonesandsusceptible toNYB (MICs remained<2mg/L).ig. 1. Proportions of susceptibility to quinolones (LVX and CIP) and ‘reverse antib
enotypes of type II topoisomerase. LVX, levoﬂoxacin; CIP, ciproﬂoxacin; NYB, nybo
uinolones and NYB was also observed with API.
u50, VRS4, VRS5, HIP07930); whereas the curves of the pat-
ern 3 strains (HIP09143, VRS1, VRS3a, HIP07920, KBSA72, KBSA56,
SA36) decreased with time. Bacterial CFU of KBSA72, KBSA56 and
SA36 decreased >103-fold after 24h.
For a more precise investigation, Mu50 and KBSA56 were inoc-
lated into CA-MHB containing 0, 8, 16, 20, 24, 28 and 32mg/L API
nd CFU were counted after 0, 0.5, 1, 3, 5, 7 and 24h of incuba-
ion. At an incubation temperature of 37 ◦C, the numbers of Mu50
ells remained in the same order of the starting time after 7h of
ncubation for all API concentrations. The cell number remained
he same 105 order after 24h in the presence of 20mg/L, and
2.0×106 CFU in the presence of 24mg/L and 28mg/L API. In
he presence of 8, 16 and 32mg/L API, however, the viable cell
ount increased from 1.73×105 to 7.20×107, from 1.81×105 to
.50×107, and from 2.31×105 to 5.13×106, respectively, after
4h. Although the differences are small, 20mg/L was the most
ffective concentration to inhibit the cell growth of Mu50. API
educed the number of bacterial cells of KBSA56 having four muta-
ions in topoisomerases: Ser80Tyr and Glu84Val in ParC; and
er84Leu and Glu88Gly in GyrA. The viable cell number decreased
rom 2.36×105 to 1.15×104 at 7h, and to 1.30×102 at 24h
32mg/L API). Unlike againstMu50, API appeared to be bactericidal
oKBSA56, decreasing thenumberof cells to <103 with a concentra-
ionof≥20mg/L. Furthermore, the cytokillingactivityofAPI against
u50andKBSA56was testedat an incubation temperatureof43 ◦C.
PI also inhibited bacterial growth of Mu50 at 43 ◦C. The number
f bacteria remained in the same order until 7 h, except at an API
oncentration of 8mg/L,which allowed a10-fold increase in CFUby
h of incubation. After 24h of incubation, all Mu50 cultures with
PI exceeded 106 CFU/mL. The drug-free culture after 24h of incu-
ation was 3.5×108 CFU/mL. API gained antimicrobial activity at
he lower concentrations against KBSA56. Viable cell counts after
xposure to 8mg/L and 16mg/L API were >104 times lower than
hat after 24h of drug-free incubation at 37 ◦C. These results indi-
ated that API is either bacteriostatic or bactericidal depending on
he target S. aureus strains. The cytokilling activity of API was more
ronounced against KBSA56 at the raised incubation temperature
f 43 ◦C (Fig. 2b). The doubly mutated GyrA (and ParC) may have a
emperature-sensitive phenotype andmay becomemore sensitive
o API at a raised temperature..3. The target of action of apigenin
To demonstrate that API acts on GyrA with Ser84Leu muta-
ion, a topoisomerase DNA cleavage assay system was employed(RAs) (NYB and API) against 17 Staphylococcus aureus clinical strains with various
; API, apigenin. The reverse pattern of minimum inhibitory concentrations between
using wild-type as well as mutated DNA gyrase subunit A [12]. As
expected, API speciﬁcally accumulated cleaved form of the sub-
strate DNA when the mutated form of GyrA was used (Fig. 3),
indicating direct inhibition of the mutated DNA gyrase in the pres-
ence of API. Note that levoﬂoxacin inhibited the wild-type gyrase
but not themutant, showing that thequinolone andAPI havemutu-
ally reverse effects on gyrase, which would explain the reverse
correlation of MICs of quinolones and API (Table 4). API inhibited
mutated gyrase with an IC50 value of 29.6M, whereas the value
for NYB was 6.7M [1]. The weaker inhibition of mutated gyrase
by API than NYB reﬂects the difference in the MICs between the
two RA agents.
3.4. Apigenin mutant selection and reverse mutants
To investigate weather API helps generate ‘reverse mutation’
allowing the mutated QRDR to return to ‘wild-type’, mutants were
selected fromAPI-susceptibleMu50 strain using an API-containing
agar plate.
Eight independent Mu50 cultures were plated on API-
containing solid medium in Falcon 150mm×15mm dishes.
According to the results of the cytokilling assay, the API con-
centration was adjusted to 20mg/L. As expected, gyrA reverse
mutant strains were detected in two of eight dishes, indicat-
ing that API also has the feature of a RA. However, we found
that API selection causes some other mutations: whole-genome
sequencing revealed that one strain acquired mutation in gyrA
outside of the QRDR (Phe480Val) and four strains acquired muta-
tion in gyrB (Leu457Phe, Glu477Asp and Ile539Phe). One strain
acquiredmutation inmurC (Arg375Ile). One of the four strainswith
gyrB(Leu457Phe) mutation was observed to have two peaks on the
476th nucleotide of rsbU (C and T). The strain had a greater num-
ber of C (the original nucleotide in Mu50), than T. A mutation of
the 476th nucleotide from C to T causes amino acid substitution of
Pro159Leu.
MICs of the eightAPI-resistant strainsweremeasured. Theback-
mutated strains had increasedMICs for API and NYB and decreased
MICs for the six tested quinolones (Table 5). Six strains without
back-mutation had an increased API MIC, but they remained resis-These analyses indicated that API has a RA feature of allowing
back-mutation in the gyrAQRDR.However, unlikeNYB, API appears
to permit a few other genetic changes that confer resistance to its
rather mild antibacterial activity.
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Fig. 2. (a) Cytokilling assay of 20mg/L apigenin (API) against 17 clinically isolated Staphylococcus aureus strains. The results roughly gave three patterns of killing curves:
pattern 1 represents API to have no effect on bacterial growth (NCTC 8325, N315); pattern 2 represents API to have some effect to inhibit bacterial growth but strains increased
the number of cells after 7h of incubation (FDA 209P, HIP09662, NRS118, HIP5836 (NJ), NRS118, Mu50, VRS4, VRS5, HIP07930); whereas the curves of the pattern 3 strains
(HIP09143, VRS1, VRS3a, HIP07920, KBSA72, KBSA56, KSA36) decreasedwith time. Bacterial CFU of KBSA72, KBSA56 and KSA36 decreased >103-fold after 24h. (b) Cytokilling
curves of graded antibiotic concentration against Mu50 and KBSA56. Mu50 and KBSA56 were inoculated into cation-adjusted Mueller–Hinton broth containing 0, 8, 16, 20,
24, 28 or 32mg/L API and CFU were counted after 0, 0.5, 1, 3, 5, 7 and 24h of incubation. The numbers of Mu50 cells remained in the same order of the starting time after
7h of incubation for all API concentrations at an incubation temperature of 37 ◦C. API reduced the number of the bacterial cells of KBSA56 having Ser84Leu and Glu88Gly
mutations in gyrA.
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Fig. 3. In vitro DNA cleavage assay shows that apigenin speciﬁcally inhibits the mutated form of DNA gyrase, whereas the mutant is resistant to levoﬂoxacin (LVX), one of
the most frequently used quinolones. In the ﬁgure, ‘S’ represents supercoiled substrate plasmid DNA pTWV228, ‘L’ is the linearised form of the plasmid, whereas ‘N’ indicates
the nicked form of the plasmid. The decrease of intensity in population ‘S’ and corresponding accumulation of ‘L’ and ‘N’ forms means failure of the DNA religation activity
by effective drugs after cleavage of the substrate DNA by DNA gyrase. wt, wild-type.
Table 5
Amino acid substitutions andminimum inhibitory concentrations (MICs) of six quinolones, nybomycin (NYB) and apigenin (API) against Staphylococcus aureusMu50mutants
selected by 20mg/L API.
Strain AA substitutiona MIC (mg/L)b
gyrA gyrB Other gene NOR OFX LVX CIP TSX SPX NYB API
Parent – – – 128 16 8 32 >128 16 0.25 4
1 – Leu457Phe rsbU(Pro159Leu) 64 16 8 32 >128 16 1 >128
2 – – murC (Arg375Ile) 128 16 8 64 >128 16 0.25 128
3 Phe480Val – – 128 32 16 32 >128 32 1 >128
4 Leu84Ser – – 8 2 1 2 0.5 0.25 >64 >128
5 – Ile539Phe – 64 32 16 32 >128 16 2 >128
6 Leu84Ser – – 8 2 1 2 0.5 0.25 >64 >128
7 – Glu477Asp – 128 16 8 32 >128 64 1 >128
8 – Ile539Phe – 128 16 8 32 >128 16 2 >128
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rA, amino acid; NOR, norﬂoxacin; OFX, oﬂoxacin; LVX, levoﬂoxacin; CIP, ciproﬂoxa
a ‘–’ indicates no AA substitution.
b MICs≤4mg/L are in bold.
. Discussion
From ancient times, ﬂavonoid-producing plants have been used
n folk and traditional medicine [13,14]. As a member of the
avones, API is found in some plants, including parsley, olive
eaves and, one of the most popular medicinal plants, chamomile
13,15,16]. Several groups have studied the activity of ﬂavones,
ncluding API, against S. aureus [6]. In in vitro-based studies, sev-
ral modes of action were reported [17–19]. However, the activity
f API towards microbes was determined as marginal or none [20],
xcept for one report presenting MICs of 3.9–15.6mg/L against S.
ureus strains [21].
In this study, screening was carried out based on the concept
f RA against quinolone-resistant bacteria [2]. Therefore, not only
uinolone-susceptible type strains but also quinolone-resistant
trains as well as those resistant to multiple antibiotics were
ncluded in the S. aureus MIC panel. As a result, we have discov-
red that API has anMIC of 2–4mg/L against S. aureus strains when
hey carry Ser84Leu mutation in gyrA. Furthermore, API exerted a
actericidal effect on three clinically isolatedMRSA strains (KSA36,
BSA72 and KBSA56). The MIC of 0.5mg/L recorded for the three
trains was the lowest of API for any clinical S. aureus strains we
ave so far tested.
Cytokilling assay revealed that API inhibits proliferation of S.
ureus strains carrying Ser84Leu mutation in gyrA (Table 4). API
educed the number of viable cells for several S. aureus strainsSX, tosuﬂoxacin; SPX, sparﬂoxacin.
(KSA36, KBSA72 and KBSA56). They were isolated in 2005 from
hospitals in the eastern and western sides of Japan. They were
characteristic in carrying gyrA(Glu88Gly) mutation. In general,
Glu88Gly mutation in gyrA is not common. We have not found any
other isolates in our collection nor in the BLAST search database of
the National Center for Biotechnology Information (NCBI) website.
KBSA56was used for further cytokilling investigation. The tem-
perature was set ﬁrst at 37 ◦C and then at 43 ◦C. API reduced CFU of
KBSA56 both at 37 ◦C and 43 ◦C. The decrease in CFUwas greater at
43 ◦C, especially at lower API concentrations (8mg/L and 16mg/L).
Regarding the cytokilling activity of ﬂavones, there is a discus-
sion that ﬂavones ‘glue’ bacterial cells and thus reduce the number
of CFUwithout killing the cells [6]. Thismight also be happening on
the tested cells in our panel. However, aggregation alone was not
enough to explain the patterns of the killing curve (Fig. 2b). CFU
of the strains carrying amino acid substitution Glu88Gly decreased
from 105 to <10 when exposed to API. Tighter binding of API to the
doubly mutated GyrA may be the reason for cytokilling of the cell
through prolonged inactivation of gyrase function.
API mutant selection was performed using Mu50. Two back-
mutated strains were obtained in a total of eight samples. Unlike
NYB, API appears to permit bacterial cells several different types
of mutations to escape from its activity. Four API-resistant strains
acquiredmutation in gyrB and became resistant both to quinolones
and API. Against these mutants, however, the NYB MIC remained
<2mg/L against all of the API-resistant Mu50-derived strains.
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[Y. Morimoto et al. / International Journa
Flavonoids were produced by plants that covered the earth’s
urface producing thick forests and wetlands in the Carbonifer-
us period (ca. 359–199 million years ago). Almost all bacteria
n old times are considered to have been exposed to ﬂavonoids
nd must have become resistant to them. Quinolones were ﬁrst
ntroduced in the 1960s by humans. Therefore, it is curious why
PI has antimicrobial activity against quinolone-resistant S. aureus
trains, whereas it is ineffective against S. aureus susceptible to
uinolones. Plants and microbes have shared the living environ-
ent since ancient times, thus some ﬂavones might have been
sed to check the overgrowth of the cohabiting micro-organisms.
he ﬁrst land-adapted plants appeared during the mid-Palaeozoic
ra, ca. 480–360 million years ago [22]. It is curious to speculate
hat API was once much more active against the soil bacteria 400
illion years ago, but accumulated QRDR mutations since then
o have become resistant to ﬂavones. Then, humans synthesised
he quinolone antibiotics for use against ﬂavone-resistant bacte-
ia, which reduced the number of ‘wild-type’ strains and increased
he number of ‘quinolone-resistant mutant’ strains having simi-
ar topoisomerases of the ancient bacteria. Thus, quinolones and
avones might have been lined historically as mutually comple-
entary RAs.
This ﬁnding of API and NYB as natural groups of RAs against
uinolone resistance suggests that the use of RAs may open a new
ra of chemotherapy that has long been suffering from the increase
n drug-resistant bacteria. RAs in nature would not be conﬁned
o quinolone resistance. Further investigation would reveal more
inds of RAs in nature. Rational use of various RAs would allow us
nally resolve the problem of the vicious cycle between antibiotics
nd antibiotic resistance.
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